


PRODUCT INFORMATION



ADU-S100

Item No. 27901

CAS Registry No.: 1638750-95-4
Formal Name: [P(R)]-5'-O-[(R)-hydroxymercaptophosphinyl]-P-thioadenylyl-(2'→5')-adenosine cyclic nucleotide, disodium salt
Synonyms: MIW815, ML RR S2-CDA
MF: C₂₀H₂₂N₁₀O₁₀P₂S₂ • 2Na
FW: 734.5
Purity: ≥98%
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

ADU-S100 is supplied as a solid. A stock solution may be made by dissolving the ADU-S100 in the solvent of choice, which should be purged with an inert gas. ADU-S100 is slightly soluble (0.1-1 mg/ml) in acetonitrile. It is also sparingly soluble (1-10 mg/ml) in water. We do not recommend storing the aqueous solution for more than one day.

Description

ADU-S100 is a cyclic dinucleotide STING agonist.¹ It induces IFN-β-dependent reporter activity in HEK293T cells expressing human STING, the human STING variants STING HAQ, STING REF, STING AQ, STING Q, or mouse STING when used at a concentration of 10 μM. Intratumoral administration of ADU-S100 (50 μg/tumor per day for three days) reduces tumor growth in wild-type, but not in *Sting1^{-/-}*, mice in a B16/F10 murine melanoma model. It decreases primary and secondary tumor volume in a 4T1 murine breast cancer model of tumor rechallenge when intratumorally administered. Unilateral intratumoral administration of ADU-S100 reduces tumor volumes in a bilateral CT26 murine colorectal cancer model. It increases tumor infiltration of natural killer (NK) cells, CD4⁺ T cells, and CD8⁺ T cells, as well as increases immune cell-induced tumor necrosis, in a GL261 murine glioma model when intratumorally administered at a dose of 50 μg/tumor.²

References

1. Corrales, L., Glickman, L.H., McWhirter, S.M., *et al.* Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity. *Cell Rep.* **11(7)**, 1018-1030 (2015).
2. Berger, G., Knelson, E.H., Jimenez-Macias, J.L., *et al.* STING activation promotes robust immune response and NK cell-mediated tumor regression in glioblastoma models. *Proc. Natl. Acad. Sci. U.S.A.* **119(28)**, e2111003119 (2022).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 07/16/2024

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD

ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM